Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock

Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, divested a total of 7,763 shares of the company's common stock on August 13, 2026, garnering a sum of $912,703. The shares were disposed of in several transactions at prices fluctuating between $115.67 and $119.52 per share. As of the current valuation, Rhythm Pharmaceuticals' stock trades at $115.55, closely hovering near its 52-week peak of $122.20.

According to InvestingPro's assessment, the stock is considered overvalued, positioning it among companies featured on the Most Overvalued list. These transactions were carried out under a Rule 10b5-1 trading plan that Mr. Garfield initiated on May 14, 2026. Post these sales, Mr. Garfield retains a personal stake of 2,295 shares in Rhythm Pharmaceuticals common stock.

Subscribers of InvestingPro gain access to an array of 13 ProTips for RYTM, complemented by a detailed Pro Research Report that distills intricate data into practical insights for this $7.94 billion biotech entity. Apart from this, Rhythm Pharmaceuticals disclosed a stronger-than-anticipated earnings report and revenue for the second quarter of 2026.

The company incurred a loss of $0.73 per share, marginally better than the estimated loss of $0.81 per share. Revenue clocked in at $71.26 million, outpacing Wall Street's forecast of $67.53 million. This accomplishment was propelled by the successful introduction of IMCIVREE, designed to combat hypothalamic obesity, and sustained expansion in therapies for Bardet-Biedl syndrome.

Furthermore, Citizens upped its price target for Rhythm Pharmaceuticals shares from $155 to $160, preserving a Market Outperform rating. This upgrade was credited to the robust launch of Imcivree, propelled by substantial patient demand. The company's management also reported over 400 sign-ups for Imcivree as of the second quarter, exceeding their initial projection of 350.

These advancements underscore Rhythm Pharmaceuticals' optimistic trajectory in the market. This account was AI-generated and subsequently vetted by a human editor. For further details, refer to the Terms and Conditions.